SURROGATE ENDPOINTS FOR OVERALL SURVIVAL (OS) IN ADVANCED MELANOMA: A TARGETED LITERATURE REVIEW (TLR) OF CORRELATION META-ANALYSES

被引：0
|
作者：
Pourrahmat, M. M. [1 ]
Leung, L. [1 ]
Kurt, M. [2 ]
Chou, E. [2 ]
Kanters, S. [1 ]
Moshyk, A. [2 ]
Hamilton, M. [2 ]
机构：
[1] Evidinno Outcomes Res Inc, Vancouver, BC, Canada
[2] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC24
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [11] Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
    Flaherty, Keith T.
    Hennig, Michael
    Lee, Sandra J.
    Ascierto, Paolo A.
    Dummer, Reinhard
    Eggermont, Alexander M. M.
    Hauschild, Axel
    Kefford, Richard
    Kirkwood, John M.
    Long, Georgina V.
    Lorigan, Paul
    Mackensen, Andreas
    McArthur, Grant
    O'Day, Steven
    Patel, Poulam M.
    Robert, Caroline
    Schadendorf, Dirk
    LANCET ONCOLOGY, 2014, 15 (03): : 297 - 304
  • [12] Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer
    Ciani, Oriana
    Buyse, Marc
    Garside, Ruth
    Peters, Jaime
    Saad, Everardo D.
    Stein, Ken
    Taylor, Rod S.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2015, 68 (07) : 833 - 842
  • [13] PROGRESSION-FREE SURVIVAL (PFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN PREVIOUSLY UNTREATED ADVANCED MELANOMA: A CORRELATION META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS)
    Leung, L.
    Chou, E.
    Kurt, M.
    Moshyk, A.
    Hamilton, M.
    Pourrahmat, M. M.
    Kanters, S.
    VALUE IN HEALTH, 2022, 25 (01) : S22 - S22
  • [14] A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
    Cooper, Katy
    Tappenden, Paul
    Cantrell, Anna
    Ennis, Kate
    BRITISH JOURNAL OF CANCER, 2020, 123 (11) : 1686 - 1696
  • [15] A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
    Katy Cooper
    Paul Tappenden
    Anna Cantrell
    Kate Ennis
    British Journal of Cancer, 2020, 123 : 1686 - 1696
  • [16] Melanoma Brain Metastases: Immunotherapy or Targeted Therapy? A Systematic Review and Meta-Analyses
    Onofrio, Livia
    Gaeta, Aurora
    D'Ecclesiis, Oriana
    Cugliari, Giovanni
    Gandini, Sara
    Queirolo, Paola
    APPLIED SCIENCES-BASEL, 2024, 14 (06):
  • [17] Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
    Takehiro Hirai
    Asuka Nemoto
    Yoshinori Ito
    Masaaki Matsuura
    Breast Cancer Research and Treatment, 2020, 181 : 189 - 198
  • [18] Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
    Hirai, Takehiro
    Nemoto, Asuka
    Ito, Yoshinori
    Matsuura, Masaaki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 189 - 198
  • [19] DISEASE-FREE SURVIVAL AS A POTENTIAL SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH EARLY-STAGE NON-SMALL CELL LUNG CANCER: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSES
    Abogunrin, S.
    Lorenzi, M.
    Cadarette, S.
    Belleli, R.
    Polito, L.
    Wissinger, E.
    VALUE IN HEALTH, 2022, 25 (12) : S3 - S4
  • [20] A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
    Haslam, Alyson
    Hey, Spencer P.
    Gill, Jennifer
    Prasad, Vinay
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 196 - 211
12345